Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D), also known as Decoy receptor 2 (DCR2) or TRAIL receptor 4 (TRAILR4), is a cell surface receptor belonging to the TNF receptor superfamily[1][3][7]. Unlike related pro-apoptotic receptors, TNFRSF10D contains a truncated cytoplasmic death domain, rendering it incapable of inducing apoptosis; instead, it acts as a decoy receptor that binds TRAIL, thereby inhibiting TRAIL-induced cell death and modulating immune and apoptotic responses[1][3][4][6]. TNFRSF10D is implicated in a range of cancers, both as a marker of tumor progression and as a regulator of tumor sensitivity to TRAIL-based therapies, with its epigenetic silencing associated with tumorigenesis in several cancer types[1][2].
Acts as a decoy receptor for TRAIL (TNF-related apoptosis-inducing ligand), inhibiting TRAIL-induced apoptosis by competing with pro-apoptotic TRAIL receptors for ligand binding[1][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D).